🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I thought the idea of ADCs was that they’re supposed to be less toxic than chemo—make it smarter 🔑 not more explosive! 🧨 Now a trick to combine more chemos?!

So proud of my friend Katie Coleman for being chosen as a featured ASCO Voice. The patient perspective, especially one representing the AYA population, is so important! Can’t wait to cheer her on in the audience! #ASCO25 #ayacsm

Super excited to have cast a vote for Narjust Florez, MD, FASCO who changed the way I view my treatment and the paradigm for patient/provider partnerships. "Cancer patients think they have to suffer," is how she put it, explaining one of the reasons that patients underreport toxciities.

Thank you so much Allison Rosen, MS. Honored to speak ASCO Voices on May 30th. I’ll also be presenting in “Beyond the Headlines: The Real Impact of Early-Onset Cancers” on Mon, June 2nd (8 am- S100bc). Come join the conversation! Such important topics!

📢 Inspiring words from our #TravelGrant recipient, Nurse Nanre Mampak from Project Pink Blue, at the #SGBCC2025! #BreastCancer #GlobalHealth #PatientAdvocacy

Proud to be awarded a Conquer Cancer #ASCO25 Merit Award! Thanks Conquer Cancer, the ASCO Foundation and to all the donors for supporting our work!

I am so grateful that our work has been awarded with a Conquer Cancer, the ASCO Foundation ASCO Merit Award! 💫 Proud to be on this list for the third time, a big thank goes to my mentors and co-authors - Looking forward to presenting our work in Chicago!🇧🇪✈️🇺🇸 OncoAlert conquer.org/news/conquer-c…

Our Heartfelt Congratulations to our AMAZING OncoAlert 🚨Faculty/Colleague & Friend Elisa Agostinetto 🇧🇪 Well Deserved Elisa!! Ping #BreastCancer Faculty Breast Matteo Lambertini, MD PhD Philippe Aftimos, MD  Evandro de Azambuja, MD, PhD Stephanie Graff, MD, FACP, FASCO 𝙅𝙚𝙨𝙪𝙨 𝘼𝙣𝙖𝙢𝙥𝙖 𝙈.𝘿, 𝙈.𝙎🧬🔬 Erika Hamilton, MD Double Whammy Dr. Kelly Shanahan

Do Topoisomerase1 ADCs work when used sequentially? Only one way to know: study the sequence prospectively. At Dana-Farber’s Breast Oncology Center, we are conducting #SATEEN, a prospective trial of SG/trastuzumab among pts with HER2+ MBC previously exposed to T-DXd. Results anticipated by 2026

Check out the #AACR25 poster session on phase 0 and phase I clinical trials on April 28th where Dr. Elia Seguí (Elia Seguí, MD) will present results from a single-arm phase 1 trial of #avutometinib (RAF/MEK inhibitor), abemaciclib, and fulvestrant in CDK4/6 inhibitor

Debunking 2 myths: 🚫More potent payload ≠ better ADC 🚫More stable ≠ better ADC Highly potent payloads have proven to be too toxic. Highly stable ADCs have been found associated with unexpected side effects (eg. ocular). Balance is key. Terrific presentation by Raffaele Colombo

I’m deeply honored to receive the #AACR #MICR MMSI Faculty Scholar in Cancer Research #Award This reflects the incredible work at #VelazquezVillarrealLab City of Hope, advancing #ColorectalCancer research, #PrecisionMedicine & #AI City of Hope | Orange County TGen PE-CGS

Our ⁦AACR President Patricia M. LoRusso⁩ Dr. LoRusso leads the placard card moment with all attendees at the #AACR25 Opening Ceremony united that #CancerResearch Saves Lives.

“When research funding is cut, #patients pay the price and a generation of discoveries is lost. We must protect the independence and integrity of science and remain focused on the #patients. This is not someone else’s problem, but ours” by AACR President Patricia M. LoRusso AACR #AACR25 Yale Cancer Center

Meaningful data on PARP inhibitor plus immune checkpoint inhibitor in patients with mutated BRCA 1/2, but also non-BRCA but other HRR mutations (eg PALB2, CHEK2, ATM, BRIP1, CDK12) or HRD-positive disease on KEYLYNK-007 presented by Dr. Tim Yap @#AACR25 AACR

🗓️ Join us at #ABC8 in Lisbon or virtually, Nov 6-8, 2025! Connect with global experts on advanced breast cancer and be part of our community. Register now: abc-lisbon.org #AdvancedBreastCancer #ABC8

Case report by Sonia Gowda from Tufts Medical Center: A patient with TNBC and mCRC in the setting of Lynch syndrome had a sustained response to pembrolizumab monotherapy, highlighting how biomarkers can guide treatment in TNBC judy garber Dana-Farber’s Breast Oncology Center ascopubs.org/doi/pdfdirect/…

PALMIRA now published on JCO. Consistent with PACE, it shows no benefit with palbo rechallenge after prior progression on palbo. Other trials found a PFS benefit, albeit limited, when the CDK4/6i is switched to abema (postMonarch) or ribo (Maintain). ascopubs.org/doi/10.1200/JC…

I have been fielding a lot of calls from my #medonc colleagues around availability of #microbiome modulating studies for #kidneycancer at City of Hope (in particular, #CBM588). The following are the two studies we have enrolling currently (limited slots remaining): 1.

In this recent Medscape Care Cues video, Erica Mayer, MD, MPH (Erica Mayer) was joined by Lisa Scace Doshier, one of her patients, to discuss strategies doctors can use to communicate with patients especially in the setting of #MetastaticBreastCancer. medscape.com/viewarticle/hr…